AI Article Synopsis
- - The study focused on Generalized Pustular Psoriasis (GPP), a rare and serious skin condition, examining its course, treatment approaches, and how often patients used healthcare services in Portugal from 2002 to 2023.
- - It assessed 59 adult patients, revealing that most had a history of another psoriasis type and faced significant health issues, with 64% requiring hospitalization and many experiencing severe symptoms such as fever and high white blood cell counts.
- - Despite treatment, 98% of patients had at least one flare-up, and only a small number showed improvement by the study's end, indicating a need for better understanding and new treatment options to alleviate the disease's impact.
Article Abstract
Objectives: Generalized pustular psoriasis (GPP) is a rare, life-threatening skin inflammatory disorder. This study aimed to describe the disease course, treatment strategies, and healthcare utilization among patients with GPP in Portugal.
Methods: This multicentric, observational, retrospective study included consecutive adult patients with GPP undergoing a dermatology evaluation in different reporting institutions by experienced dermatologists between 2002 and 2023.
Results: A total of 59 patients were assessed. Most of the cohort had a previous history of plaque psoriasis (71%) and 83% presented at least one comorbidity. At the initial encounter, 64% of the cohort needed hospitalization. Systemic involvement was common, including fever (37%), and elevated white blood cell count and erythrocyte sedimentation rate/C-reactive protein (49%). Nearly, 73% of patients initiated systemic drugs, and 70% had to discontinue the first treatment. During the study, 98% of patients experienced at least one flare. At the last visit, 3.4% of patients had died, and 71.2% exhibited signs of active disease despite undergoing treatment.
Conclusions: Our study demonstrates that GPP is a chronic, debilitating condition associated with systemic involvement, frequent flares, and hospitalizations, despite receiving multiple systemic treatments. Improved disease awareness and new treatments are needed to improve patient care and decrease the burden of the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2024.2345728 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date.
View Article and Find Full Text PDFAcute generalized exanthematous pustulosis is a severe cutaneous adverse reaction characterized by the rapid onset of nonfollicular, sterile pustules on an erythematous base, typically accompanied by fever (≥38 °C), neutrophilia (7.0 × 10⁹/L), and characteristic histopathological features. This case report presents the first documented instance of acute generalized exanthematous pustulosis after hyaluronic acid viscosupplementation.
View Article and Find Full Text PDFA Hybrid Model for Psoriasis Subtype Classification: Integrating Multi Transfer Learning and Hard Voting Ensemble Models.
Diagnostics (Basel)
December 2024
Department of Dermatology, Faculty of Medicine, Firat University, 23200 Elazig, Turkey.
Psoriasis is a chronic, immune-mediated skin disease characterized by lifelong persistence and fluctuating symptoms. The clinical similarities among its subtypes and the diversity of symptoms present challenges in diagnosis. Early diagnosis plays a vital role in preventing the spread of lesions and improving patients' quality of life.
View Article and Find Full Text PDFEruption of Generalized Pustular Psoriasis Following Initiation of Adalimumab for Hidradenitis Suppurativa: A Case Report.
Cureus
December 2024
Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Rarely, tumor necrosis factor (TNF)-α inhibitors can paradoxically induce eruptions of psoriasis with generalized pustular psoriasis being among the least common presentations. We report a patient who presented with a generalized pustular eruption following adalimumab therapy for hidradenitis suppurativa (HS). The diagnosis of generalized pustular psoriasis was confirmed with a biopsy showing neutrophilic spongiosis and intraepidermal pustulosis.
View Article and Find Full Text PDFLong-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study.
J Dermatolog Treat
December 2025
Department of Dermatology, Children's Hospital Affiliated to Kunming Medical University, Kunming, China.
To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!